Tivic Health Systems Stock (NASDAQ:TIVC)

Revenue Ownership Financials Chart Transcripts

Previous Close

$0.29

52W Range

$0.26 - $5.60

50D Avg

$0.96

200D Avg

$2.09

Market Cap

$313.06K

Avg Vol (3M)

$382.26K

Beta

1.84

Div Yield

-

TIVC Company Profile

Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

52

IPO Date

Nov 11, 2021

Website

TIVC Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24	Dec 23	Dec 22
Shipping and Handling	$1.00K	$3.00K	$3.00K

Fiscal year ends in Dec 25 | Currency in USD

TIVC Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$382.00K	$780.00K	$1.18M
Operating Income	$-768.00K	$-5.66M	$-8.24M
Net Income	-	$-5.66M	$-8.24M
EBITDA	$-768.00K	$-5.31M	$-8.06M
Basic EPS	-	$-19.67	$-176.72
Diluted EPS	-	$-19.67	$-176.72

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 14, 25 | 4:30 PM

Q2 25Aug 14, 25 | 4:30 PM

Q1 25May 15, 25 | 4:30 PM

Peer Comparison

Ticker	Company
NCEL	NewcelX Ltd.
WINT	Windtree Therapeutics, Inc.
VRAX	Virax Biolabs Group Limited
BJDX	Bluejay Diagnostics, Inc.
PRFX	PRF Technologies Ltd.
MLEC	Moolec Science S.A.
ELAB	PMGC Holdings Inc.